Gujarat Kidney IPO GMP

December 24, 2025 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

Gujarat Kidney & Super Speciality IPO opens for subscription from December 22 to 24, 2025, with allotment on December 26 and listing on BSE and NSE on December 30, 2025. The book-built issue raises ₹250.80 crore entirely through a fresh issue of 2.20 crore shares at a price band of ₹108 to ₹114 per share. Gujarat Kidney operates super-speciality hospitals focusing on nephrology, urology, and multi-specialty care, with 670 employees and 327 consultants serving patients across Gujarat. The Gujarat Kidney IPO proceeds fund hospital acquisitions, capex for new facilities in Vadodara, robotics equipment, debt repayment, and inorganic growth.

₹00

Latest IPO GMP

Last updated on 29 Dec 2025 20.00

₹114

IPO Offer Price

*cut off price

₹

Listing Price

Listing Date 30/12/2025

Expert Opinions

Market sentiment for Gujarat Kidney IPO is positive, driven by strong healthcare sector tailwinds and the company’s explosive 637% revenue growth to ₹40.40 crore with 454% PAT increase to ₹9.50 crore in FY 2025. Company strengths include specialized nephrology/urology focus across 6 hospitals with ~340 beds, 24% EBITDA margins, and 670 employees serving Gujarat’s medical tourism hub.

Risks encompass execution challenges in acquisitions like Parekhs Hospital, high capex needs, regulatory compliance, and doctor retention in competitive markets. Valuation analysis of Gujarat Kidney IPO in 2025 shows a Return on Equity (ROE) of 36.61%, ROCE of 37.65%, and Net Asset Value (NAV) of ₹5.04.. Long-term investment perspective is compelling given rising kidney disease incidence, healthcare spending growth to ₹7.7 trillion by FY27, and expansion into tier-1 cities like Ahmedabad.

Investor Considerations

Investors in Gujarat Kidney IPO should consider the company’s explosive growth, with revenue surging 637% to ₹40.40 crore and PAT rising 454% to ₹9.50 crore in FY 2025 from FY24, supported by 6 hospitals, ~340 beds, and specialized nephrology/urology services. Sector outlook is strong amid India’s healthcare expansion to ₹7.7 trillion by FY27 and rising kidney disease incidence.

Valuation analysis of Gujarat Kidney IPO in 2025 shows a Price to Book Value of 22.62, PAT Margin of 23.61%, and Debt/Equity ratio of 0.15, reflecting premium pricing with high profitability and low leverage. Growth prospects include hospital acquisitions, Vadodara expansion, robotics adoption, and debt reduction enhancing capacity. Risk factors encompass execution delays, doctor retention, regulatory compliance, and high capex needs. Long-term investors benefit from healthcare tailwinds and super-speciality demand, while short-term goals face listing volatility and integration risks.